Drawbridge's POC HbA1c test cleared for Europe

LabPulse.com staff writers
Feb 3, 2020
2019 05 02 23 38 2538 Check Mark 400

The OneDraw single-use, point-of-care (POC) test for hemoglobin A1c (HbA1c) has the CE Mark for sale in European markets, according to its developer, Drawbridge Health, a private company founded by General Electric.

The product is intended for long-term monitoring of blood sugar in adults with diabetes, noted Drawbridge, which is based in Menlo Park, CA. Using the device, medical professionals can collect blood via light vacuum suction as an alternative to methods that involve hypodermic needles or finger sticks. Specimens are taken from the device through a removable cartridge and mailed to a certified lab for analysis.

Drawbridge will introduce the product in "select countries" in Europe this year, the company said in a statement. The OneDraw test was cleared by the U.S. Food and Drug Administration in August 2019.

Latest in 510(k)
Digital Pathology Cytology Social
Leica Biosystems granted FDA clearance for Class II mismatch repair panel
April 3, 2023
Fda Button Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
March 20, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
May 11, 2023
Football Player Concussion Social
FDA grants clearance to Abbott for first commercial laboratory test to detect traumatic brain injury
March 7, 2023
Related Stories
2020 01 24 22 29 3138 Man Black Barber 400
Diagnostic Technologies
Barbershop POC blood tests pick up undiagnosed diabetes
2019 10 25 22 16 3822 Lab Hb A1c Diabetes 400
Point-of-Care Testing
Self-testing helps drive demand for bustling HbA1c market
2019 07 31 21 43 0672 Diabetes Type 2 400
Healthcare Reform
Point-of-care testing tackles diabetes risk in Texas
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in 510(k)
Leica Biosystems granted FDA clearance for Class II mismatch repair panel
The Bond MMR Antibody Panel is available for clinical use on its automated Bond-III and Bond-Max immunohistochemistry instruments.
April 3, 2023
Digital Pathology Cytology Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Becton Dickinson nabs FDA clearance for infectious vaginitis molecular test
The BD vaginal panel running on the high-throughput BD Cor molecular diagnostic system tests for multiple common types of vaginitis using only a swab and one test.
March 16, 2023
Bd Vaginal Panel Cor System
FDA grants clearance to Abbott for first commercial laboratory test to detect traumatic brain injury
The test runs on Abbott's Alinity i laboratory immunoassay instrument, providing a result in 18 minutes to help clinicians quickly assess concussion and triage patients, Abbott said. Negative results rule out the need for a CT scan.
March 7, 2023
Football Player Concussion Social
Copan Diagnostics receives second FDA clearance for semiautomated preanalytical processor
With this second clearance, Colibri can prepare microbial suspensions for antibiotic susceptibility testing with the BioMérieux Vitek 2 system.
October 11, 2022
Lab Virus Bacteria Research
OIG: FDA recommendations for future pandemics
OIG offered numerous recommendations to manage such infectious disease emergencies, saying the FDA should access and, when appropriate, revise its guidance for Emergency Use Authorization (EUA) submissions for tests.
September 21, 2022
2021 11 29 23 50 3003 Fda Button 20211129235739
Week in Review: Multicancer early detection at ESMO, DiaSorin nabs FDA clearance for COVID-19 kit, IVD industry urges Congress to enact SALSA, and more
Dear LabPulse.com member,
September 14, 2022
FDA grants 510(k) clearance to DiaSorin for COVID-19 kit
The kit, which runs on DiaSorin's Liaison MDX molecular diagnostics system, provides a sample-to-answer test for the detection of SARS-CoV-2 directly from nasopharyngeal or nasal swab specimens.
September 13, 2022
2021 08 23 18 25 2180 Covid Treatment Doctor 400
PixCell Medical, Insight Medical to distribute hematology analyzer
PixCell said that its HemoScreen hematology analyzer delivers lab-grade diagnostics at the point of care without the need for external reagents or extensive training.
September 5, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Cue Health requests FDA de novo clearance for at-home flu test
Clearance would permit the test to be used at home and elsewhere at the point-of-care (POC).
September 1, 2022
2022 09 02 19 52 9683 Flu Season Ahead 400
NanoDx, SkyWater launch nano biosensor
The companies said that as a result of the development, NanoDx is ready to prepare and submit the product for review by the U.S. Food and Drug Administration (FDA) with the aim of eventually commercializing a product based on the technology.
August 25, 2022
2021 06 30 22 19 4138 Digital Science Lab 400
FDA issues updated reagent, instrument guidance
The agency said that it revised the current guidance to include point-of-care in vitro diagnostic (IVD) devices in certain situations, flowcharts, updates to examples, and further clarification of terminology.
August 15, 2022
2021 11 29 23 50 3003 Fda Button 20211129235739
Page 1 of 16
Next Page